Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2150 • ACR Convergence 2022
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Federica Lumetti¹, Alarico Ariani², Camilla Coccolini³, Carlo Salvarani⁴ and Gilda Sandri⁴, ¹Rheumatology Unit, AUSL of Modena and Azienda Ospedaliero Universitaria of Modena, Modena, Italy, ²Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria of Parma, Parma, Emilia-Romagna, Italy, ³Università di Modena e Reggio Emilia, Modena, Italy, ⁴Rheumatology Unit, Azienda Ospedaliero Universitaria of Modena, Modena, Italy
Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…
Abstract Number: 0292 • ACR Convergence 2022
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Andrea Rubbert-Roth¹, Adriana Kakehasi², Tsutomu Takeuchi³, Marc Schmalzing⁴, Hannah Palac⁵, Jianzhong Liu⁵, Samuel Anyanwu⁵, Ralph Lippe⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³Keio University and Saitama Medical University, Tokyo, Japan, ⁴University Hospital Wuerzburg, Wuerzburg, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc, Wiesbaden, Germany, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…
Abstract Number: 0510 • ACR Convergence 2022
MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Christina Charles-Schoeman¹, Ernest Choy², Iain B McInnes³, Eduardo Mysler⁴, Peter Nash⁵, Kunihiro Yamaoka⁶, Ralph Lippe⁷, Nasser Khan⁸, Anna K Shmagel⁹, Hannah Palac⁹, Jessica Suboticki¹⁰ and Jeffrey Curtis¹¹, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Sunshine Coast, Australia, ⁶Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸AbbVie, Inc., Abbott Park, IL, ⁹AbbVie, Inc., North Chicago, IL, ¹⁰AbbVie, Inc., Mettawa, IL, ¹¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with untreated immune-mediated inflammatory diseases, such as RA, PsA, and AS, are at increased risk for major adverse cardiovascular events (MACE) and venous…
Abstract Number: 1017 • ACR Convergence 2022
Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies
William Tillett¹, Laura Coates², Marijn Vis³, Joseph Merola⁴, Enrique R Soriano⁵, Michelle Perate⁶, May Shawi⁷, Miriam Zimmermann⁸, Emmanouil Rampakakis⁹, Mohamed Sharaf¹⁰, Peter Nash¹¹ and Philip Helliwell¹², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Erasmus MC Universitair Medisch Centrum, Rotterdam, Netherlands, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁹McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ¹⁰Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ¹¹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Though continuous composite measures of disease activity for psoriatic arthritis (PsA) assessment exist, abbreviated measures that are more feasible for screening in routine clinical…
Abstract Number: 1044 • ACR Convergence 2022
Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain
cristina Valero-Martinez¹, Judith Font Urguelles², Meritxell Sallés³, BEATRIZ E. JOVEN⁴, Felipe Julio Ramirez Garcia⁵, Xavier Juanola⁶, Raquel Almodóvar⁷, ana Laiz⁸, Mireia Moreno⁹, Manel Pujol¹⁰, Luis Sala-Icardo¹¹, Santos Castañeda¹² and Rosario Garcia-Vicuña¹, ¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Althaia Xarxa Assistencial Universitària, Manresa, Spain, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Hospital Clínic, Barcelona, Spain, ⁶Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, Spain, ⁷Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁸Unitat Territorial de Reumatologia Sant Pau-Dos de Maig, Barcelona, Spain, ⁹Hospital Universitari Parc Taulí, Sabadell, Spain, ¹⁰Hospital Universitario MútuaTerrassa, Terrassa, Spain, ¹¹Hospital Universitario de Torrejón de Ardoz, Madrid, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Combined biological or targeted therapy (CBTT) is rarely considered in clinical practice due to contraindication in guidelines, potential safety concerns and high costs. However,…
Abstract Number: 1260 • ACR Convergence 2022
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Irina Gessl¹, Mihaela Popescu², Gabriela supp³, Thomas Deimel¹, Paul Studenic¹, Martina Durechova³, michael zauner³, Josef Smolen¹ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: In inflammatory arthritis swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, the association of tenderness with radiographic…
Abstract Number: 1502 • ACR Convergence 2022
Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams
Evan Siegel¹, Amit Garg², Jeffrey Carter³, Laura Simone⁴ and Marykate Nelson⁵, ¹Georgetown University School of Medicine, Washington, DC, ²Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, ³PRIME Education, Boynton Beach, FL, ⁴PRIME Education, Omaha, NE, ⁵PRIME Education, Drexel Hill, PA
Background/Purpose: The optimal care of psoriatic arthritis (PsA) requires effective collaboration between rheumatology and dermatology teams. We executed an initiative to identify gaps and inform…
Abstract Number: 1673 • ACR Convergence 2022
Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort
SABRINA HAMROUN¹, Marion Couderc², Rene-Marc Flipo³, Jérémie SELLAM⁴, Christophe Richez⁵, Emmanuelle Dernis⁶, Aline Frazier-Mironer⁷, Laure Gossec⁸, elisabeth gervais⁹, Hubert Marotte¹⁰, Laetitia Dunogeant¹¹, Cédric Lukas¹², Alban DEROUX¹³, Nathalie Costedoat-Chalumeau¹⁴ and Anna Molto¹⁵, ¹Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, ²University Hospital, Clermont-Ferrand, France, ³CHU Lille, Boulogne-Billancourt, France, ⁴Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶LE MANS general hospital, LE MANS, France, ⁷APHP Hôpital Lariboisire, Paris, France, ⁸Sorbonne Université, Paris, France, ⁹chu poitiers, Poitiers, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹Hospital of Aix en Provence, Marseille, France, ¹²University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ¹³CHU Grenoble, Grenoble, France, ¹⁴Inserm DR Paris 5, Paris, France, ¹⁵Rheumatology Department, Cochin Hospital, APHP, Paris, France
Background/Purpose: Spondyloarthritis (SpA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge about…
Abstract Number: 2117 • ACR Convergence 2022
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
Philip J Mease¹, Laura Coates², Robert Landewé³, Iain B McInnes⁴, Christopher Ritchlin⁵, Tatsuya Atsumi⁶, Frank Behrens⁷, Dafna Gladman⁸, Laure Gossec⁹, Peter Nash¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Jason Coarse¹², Adam R Prickett¹³ and Alice Gottlieb¹⁴, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Amsterdam University Medical Center, Meerssen, Netherlands, ⁴Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Hokkaido University, Sapporo, Japan, ⁷Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁸Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁹Sorbonne Université, Paris, France, ¹⁰School of Medicine, Griffith University, Sunshine Coast, Australia, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹³UCB Pharma, Brussels, Belgium, ¹⁴Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a disease with multiple manifestations; it is important that the efficacy of new interventions is assessed by composite endpoints across…
Abstract Number: 2134 • ACR Convergence 2022
Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
Richard Warren¹, Howard Sofen², Shinichi Imafuku³, Jacek C. Szepietowski⁴, Andrew Blauvelt⁵, Lynda Spelman⁶, Jessica Toms⁷, Alex Buck⁸, Subhashis Banerjee⁷ and Alan Menter⁹, ¹The University of Manchester, Manchester, United Kingdom, ²UCLA School of Medicine, Los Angeles, CA, ³Fukuoka University Hospital, Fukuoka, Japan, ⁴Wroclaw Medical University, Wroclaw, Poland, ⁵Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ⁶Veracity Clinical Research, Woolloongabba, Australia, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb; Cytel Inc, Princeton, ⁹Baylor University Medical Center, Dallas, TX
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signalling of key cytokines (eg, IL-23 and Type I IFN) involved in the pathogenesis…
Abstract Number: 2151 • ACR Convergence 2022
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
Kurt de Vlam¹, Peter Taylor², Philip J Mease³, Paul Peloso⁴, Dieter Wetzel⁵, Nicolai Brun⁵, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowinska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Frank Behrens¹², ¹University Hospitals Leuven, Leuven, Belgium, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴ACELYRIN, Naples, FL, ⁵Affibody AB, Solna, Sweden, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany
Background/Purpose: PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement.…
Abstract Number: 0308 • ACR Convergence 2022
Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Joseph Merola¹, Kristina Callis-Duffin², Byron Padilla³, Cuiyong Yue⁴, Huzefa Photowala⁴, Blair Kaplan⁴ and Iain B McInnes⁵, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²University of Utah, Salt Lake City, UT, ³AbbVie, Inc., Waukegan, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Risankizumab (RZB), a fully humanized IgG1 monoclonal antibody inhibitor of IL-23, is a therapeutic agent approved for the treatment of active psoriatic arthritis (PsA)…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 1018 • ACR Convergence 2022
Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study
Dafna Gladman¹, Laura Coates², Laure Gossec³, Jacob Aelion⁴, Jitendra Vasandani⁵, Sue Cheng⁶, Lihua Tang⁶, Shauna Jardon⁷, Sven Richter⁶ and Philip J Mease⁸, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Sorbonne Université, Paris, France, ⁴West Tennessee Research Institute, Jackson, TN, ⁵West Texas Clinical Research, Lubbock, TX, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Amgen Inc., Gilbert, AZ, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Oligoarticular psoriatic arthritis (PsA) is commonly reported in early disease. Although fewer joints are involved, there may be significant impact on patients’ (pts) quality…
Abstract Number: 1045 • ACR Convergence 2022
Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images
Marina Tortosa Cabanas, CARLOS ANTONIO GUILLEN ASTETE and Africa Andreu Suarez, Ramon y Cajal University Hospital, Madrid, Spain
Background/Purpose: Enthesitis is the base of the pathophysiology of spondyloarthritis. Recently, our research group has shown that computer analysis of static images can be used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].